Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,383Revenue (TTM) $M1,702Net Margin (%)-6.6Altman Z-Score5.8
Enterprise Value $M20,671EPS (TTM) $-0.5Operating Margin %0.6Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-4.0Higher ROA y-yY
Price/Book18.510-y EBITDA Growth Rate %--Quick Ratio2.2Cash flow > EarningsY
Price/Sales12.45-y EBITDA Growth Rate %--Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow117y-y EBITDA Growth Rate %--ROA % (ttm)-4.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-11.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M248ROIC % (ttm)3.1Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

VRTX is held by these investors:

VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Arbuckle Stuart AEVP\Chief Commercial Officer 2017-02-13Sell3,792$88.39-2.62view
ALTSHULER DAVIDEVP, Global Research and CSO 2017-02-13Sell6,403$87.68-1.84view
LEIDEN JEFFREY MCEO & President 2017-02-13Sell23,904$87.68-1.84view
Sachdev AmitEVP, CRO 2017-02-13Sell7,684$87.68-1.84view
Chodakewitz JeffreyEVP GMDA, CMO 2017-02-13Sell5,122$87.67-1.83view
SMITH IAN FEVP, CFO & COO 2017-02-13Sell3,842$87.66-1.81view
Parini MichaelEVP, CLO & CAO 2017-02-01Sell3,450$85.980.1view
Chodakewitz JeffreyEVP GMDA, CMO 2017-02-01Sell1,900$85.740.38view
BOGER JOSHUA SDirector 2017-01-11Sell8,000$82.484.35view
BOGER JOSHUA SDirector 2017-01-04Sell6,500$77.1311.59view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
    Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 
    Piotroski F-Score in the Real World Dec 19 2016 
    Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
    Edward Owens Top 2nd Quarter Investments Aug 03 2016 
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 

    More From Other Websites
    Inside Vertex’s Revenue Expectations for 2017 Feb 24 2017
    Vertex Expects Modest Revenue Growth in This Feb 24 2017
    Understanding Vertex’s Analyst Recommendations Feb 24 2017
    Headcount at ​Vertex surges in 2016, hitting four-year high Feb 23 2017
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 10-K, Annual Report Feb 23 2017
    Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and... Feb 13 2017
    5 Toxic Stocks to Dump or Play Short for Gains Feb 09 2017
    Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen Jan 27 2017
    Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals Jan 27 2017
    Blog Coverage Celgene Acquires Delinia; Set to Expand Inflammation and Immunology Portfolio Jan 27 2017
    Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q4, 2016 By the Numbers : January 26, 2017 Jan 26 2017
    Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up Jan 26 2017
    Edited Transcript of VRTX earnings conference call or presentation 25-Jan-17 9:30pm GMT Jan 25 2017
    Vertex tops Street 4Q forecasts Jan 25 2017
    Vertex tops Street 4Q forecasts Jan 25 2017
    [$$] Vertex Pharmaceuticals Swings to Profit Jan 25 2017
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 25 2017
    Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results Jan 25 2017
    The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda... Jan 25 2017
    Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex Jan 11 2017
    Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First... Dec 19 2016
    Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First... Dec 19 2016
    Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies... Nov 07 2016
    Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO®... Oct 27 2016
    Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors... Oct 25 2016
    Vertex Reports Third Quarter 2016 Financial Results Oct 25 2016
    Vertex to Announce Third Quarter 2016 Financial Results on October 25 Oct 07 2016
    U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with... Sep 28 2016
    Vertex to Present at Upcoming Investor Conferences Sep 09 2016
    Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the... Aug 15 2016
    Vertex Reports Second Quarter 2016 Financial Results Jul 27 2016
    Vertex to Announce Second Quarter 2016 Financial Results on July 27 Jul 14 2016
    Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™... Jul 06 2016
    Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI®... Jun 10 2016
    U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI®... May 31 2016
    Vertex Reports First Quarter 2016 Financial Results Apr 27 2016
    Vertex to Announce First Quarter 2016 Financial Results on April 27 Apr 15 2016
    UK cost agency says "no" to pricey Vertex cystic fibrosis drug Mar 22 2016
    Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to... Mar 08 2016
    Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to... Mar 08 2016
    US STOCKS-Wall St rallies, S&P back above 14-day moving average Sep 24 2014
    US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
    US STOCKS-S&P 500 rebounds with energy shares; Dow dips Sep 11 2014
    US STOCKS-Wall St down slightly, financials help limit losses Sep 11 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)